Informed by the European Union Experience: What the United States Can Anticipate and Learn from the European Union\u27s Regulatory Approach to Biosimilars by Gitter, Donna M.
GITTER.DOCX (DO NOT DELETE) 4/12/2011 8:37 AM 
 
559 
Informed by the European Union Experience:  
What the United States Can Anticipate and Learn  
from the European Union’s Regulatory  
Approach to Biosimilars 
Donna M. Gitter∗ 
I.   INTRODUCTION ....................................................................................... 560 
II.    THE BIOLOGICS PRICE COMPETITION AND INNOVATION  ACT OF 
2009 ........................................................................................................ 564 
A.  The Follow-On Biologic Application and Approval Process  
Under the BPCIA .......................................................................... 564 
B.  Exclusivity Provisions for Reference Biologics Pursuant to 
the BPCIA ...................................................................................... 566 
C.  Patent Infringement Issues Relating to the BPCIA .................... 568 
III.    THE EUROPEAN UNION LEGISLATIVE FRAMEWORK FOR BIOSIMILARS .... 569 
IV.    REGULATORY AND POLICY ISSUES RAISED BY AN ABBREVIATED 
APPROVAL PATHWAY FOR BIOLOGICS IN LIGHT OF THE EU 
EXPERIENCE ............................................................................................ 575 
A.  The Challenge of Assessing Comparability ................................. 575 
B.  The Difficulty of Assessing Interchangeability of the 
Reference and Biosimilar Products ............................................. 580 
C.  The Establishment of Immunogenicity Testing, 
Pharmacovigilance, and Risk Management Plans ...................... 582 
D.  The Naming of Follow-On Biological Products .......................... 586 
E.  Extrapolation of Indications ........................................................ 589 
F.  The Possibility of Extensions to the Term of Data 
Exclusivity ...................................................................................... 590 
V.    CONCLUSION .......................................................................................... 592 
 
 
 ∗ Associate Professor of Law, Baruch College, New York, New York; J.D., Univer-
sity of Pennsylvania Law School; B.A., Cornell University College of Arts and 
Sciences.  Donna.Gitter@Baruch.cuny.edu.  I would like to thank Professor Jordan 
Paradise for inviting me to contribute this work to the roundtable event “Follow-On 
Biologics: Implementation Challenges and Opportunities” held at Seton Hall Uni-
versity School of Law in October 2010 and the Seton Hall Law Review issue devoted to 
this event.  Thanks are due as well to the participants at that roundtable for their 
helpful suggestions. 
GITTER.DOCX (DO NOT DELETE) 4/12/2011  8:37 AM 
560 SETON HALL LAW REVIEW [Vol. 41:559 
I. INTRODUCTION 
Recombinant DNA technology has enabled the development of 
a variety of biopharmaceuticals, also known as biological products or 
biologics.
1
  These products, which are made by or derived from living 
organisms using biotechnology, include erythropoietin, granulocyte 
colony-stimulating factors, human growth hormone, interferons, and 
vaccines, among others.
2
  In both the United States and the European 
Union (EU), the patents for many biologics have recently expired or 
will soon do so.  Thus, pharmaceutical firms in both regions currently 
focus on developing alternative versions of biologic products,
3
 re-
ferred to as biosimilars, follow-on biologics, or follow-on protein 
products.
4
 
Unlike traditional chemical pharmaceuticals, for which precise 
generic versions can be produced, biologics are inherently variable 
and cannot be manufactured as true generic equivalents.
5
  Biologics 
have complex three-dimensional structures of high molecular weight, 
unlike traditional chemical drugs, which are of lower molecular 
weight and simpler in structure.
6
  Consequently, current analytical 
techniques cannot characterize biologics with sufficient precision to 
confirm structural equivalence with reference molecules, meaning 
that biosimilars typically differ from their reference drug in ways that 
traditional chemical pharmaceuticals do not.
7
 
 
 1 See Håkan Mellstedt et al., The Challenge of Biosimilars, 19 ANNALS ONCOLOGY 
411, 411 (2008). 
 2 See id.; Steven Simoens, Health Economics of Market Access for Biopharmaceuticals 
and Biosimilars, 12 J. MED. ECON. 211, 212–13 (2009).   
 3 See Mellstedt et al., supra note 1, at 411.   
 4 See Donna M. Gitter, Innovators and Imitators: An Analysis of Proposed Legislation 
Implementing an Abbreviated Approval Pathway for Follow-On Biologics in the United States, 
35 FLA. ST. U.L. REV. 555, 558 n.7 (2008) (noting that the term “follow-on biologic” 
refers to “proteins and peptides that are intended to be sufficiently similar to a prod-
uct already approved under the Federal Food, Drug, and Cosmetic Act or licensed 
under the Public Health Service Act to permit the applicant to rely on certain exist-
ing scientific knowledge about the safety and effectiveness of the approved protein 
product” (citation omitted)); Huub Schellekens & Ellen Moors, Clinical Comparability 
and European Biosimilar Regulations, 28 NATURE BIOTECH. 28, 28 (2010) (noting that 
the EU typically uses the term “biosimilar”).  
 5 See Mellstedt et al., supra note 1, at 412.   
 6 See JUDITH A. JOHNSON, CONG. RESEARCH SERV., FDA REGULATION OF FOLLOW-ON 
BIOLOGICS 9 (Apr. 26, 2010), available at http://www.primaryimmune.org/advocacy_ 
center/pdfs/health_care_reform/Biosimilars_Congressional_Research_Service 
_Report.pdf; see also Simoens, supra note 2, at 211. 
 7 See Huub Schellekens, Biosimilar Therapeutics—What Do We Need to Consider?, 2 
NEPHROLOGY DIALYSIS TRANSPLANTATION PLUS (SUPP. 1) i27, i27 (2009); see also Gitter, 
supra note 4, at 560–61; Simoens, supra note 2, at 212–13 (describing the differences 
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The complexity and heterogeneity of biologics derive largely 
from the manufacturing processes used to produce them.  Biologics 
are made within living cells, and minute changes in the process can 
result in differences in quality, safety, and efficacy.
8
  Thus, biologics 
differ within a single batch, from one batch to another made by the 
same company, and among companies producing the same biologic.
9
  
In contrast, traditional chemical drugs are synthesized using a pre-
dictable process that creates identical versions of the innovator 
drug.
10
 
The inherent unpredictability of biologics, whether they are in-
novator or follow-on products, also arises from the fact that biologics 
raise issues of immunogenicity.  Unlike traditional chemical pharma-
ceutical products, most biologics stimulate an immune response in 
the human body, prompting the formation of antibodies that may af-
fect human health.
11
 
Thus, due to their complex structures, sensitivity to the manu-
facturing process, and tendency toward immunogenicity, biosimilars 
cannot be considered generic biopharmaceuticals, but rather new, 
non-innovative products that are similar, but not identical, to a refer-
ence biopharmaceutical product in terms of efficacy and safety.
12
 
Notwithstanding the challenges in manufacturing biosimilars, 
the EU successfully implemented an abbreviated approval pathway 
for follow-on biologics in 2005.
13
  An abbreviated approval pathway 
for biologics permits a pharmaceutical company applying for regula-
tory approval to rely, to at least some extent, on the regulatory au-
thority’s conclusions regarding the quality, safety, and efficacy of an 
approved reference product.
14
  In this way, the manufacturer of the 
follow-on product avoids some, though not necessarily all, of the cost-
 
between biologics and traditional chemical pharmaceuticals, which render the for-
mer more complex, difficult to characterize, and harder to manufacture than the lat-
ter).   
 8 See Schellekens, supra note 7, at i27–i28.   
 9 See Gitter, supra note 4, at 561; Schellekens, supra note 7, at i27–i28.  Moreover, 
biosimilar manufacturers do not have access to the manufacturing processes of inno-
vator products because this information is proprietary, rendering precise replication 
of the reference product impossible.  Mellstedt et al., supra note 1, at 412. 
 10 See Simoens, supra note 2, at 211. 
 11 See Gitter, supra note 4, at 561; Schellekens, supra note 7, at i29. 
 12 See Mellstedt et al., supra note 1, at 411, 415. 
 13 See Meredith Waldman, U.S. Health Bill Promises Changes for Biomedical Research-
ers, 464 NATURE 479, 479 (2010). 
 14 See Schellekens, supra note 7, at i31. 
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ly pre-clinical and clinical testing
15
 necessary for regulatory approval.
16
  
As of this writing, the European Medicines Agency (EMA), the Euro-
pean equivalent of the U.S. Food and Drug Administration (FDA),
17
 
has granted marketing authorization to fourteen biosimilar prod-
ucts.
18
 
In the United States, the Hatch-Waxman Act (HWA) has pro-
vided an abbreviated approval pathway for traditional chemical 
pharmaceuticals since 1984.
19
  For these pharmaceuticals, it is rela-
tively easy to demonstrate that a generic product is equivalent to the 
reference drug.  Experts have noted that “[a]ll that is required is 
proof that the generic product contains the identical chemical com-
position as the innovator product and a bioavailability study showing 
that the pharmacokinetic properties of the generic and reference 
products are similar.”
20
 
After years of debate in the United States regarding an abbre-
viated approval pathway for follow-on biologics analogous to the 
HWA for traditional pharmaceuticals,
21
 on March 23, 2010, President 
 
 15 Pre-clinical trials, sometimes called non-clinical trials, test a pharmaceutical 
product in a lab or on animals, while clinical trials test the drug in humans.  RACHEL 
CHU & MEIR PUGATCH, STOCKHOLM NETWORK, BIOGENERICS OR BIOSIMILARS? 
DISCUSSING THE PRESENT, CONSIDERING THE FUTURE 9 n.9 (2009), available at 
http://www.stockholm-network.org/downloads/publications/Biosimilars_final.pdf . 
 16 See Schellekens, supra note 7, at i31.  “The amount of data required for market 
approval of biosimilars will be more than for a typical generic drug application but 
less than for a full new biopharmaceutical application.”  Id. 
 17 Brian A. Liang, Regulating Follow-on Biologics, 44 HARV. J. ON LEGIS. 363, 397 
(2007).  The EMA, which was reorganized in 2009, was formerly known by the 
acronym EMEA.  EMEA Becomes EMA, PMLIVE INTELLIGENCE ONLINE (Dec. 14, 2009), 
http://www.pmlive.com/find_an_article/allarticles/categories/General/2009/dece
mber/news/emea_becomes_ema. 
 18 E-mail from Anna Nagielska, Document and Information Services, European 
Medicines Agency, to author (July 23, 2010, 06:47 EST) (on file with author).   
 19 Pub. L. No. 98-417, 98 Stat. 1585 (1984) (amending the Federal Food, Drug, 
and Cosmetic Act Pub. L. 75-717, § 505(j), 52 Stat. 1040 (1938), codified at 21 U.S.C. 
§ 355(j) (2010)). 
 20 Mellstedt et al., supra note 1, at 412 (citation omitted).  Pharmacokinetics is 
described as “what the body does to a drug” and “refers to the movement of drug in-
to, through, and out of the body—the time course of its absorption, bioavailability, 
distribution, metabolism, and excretion.”  Clinical Pharmacology, Pharmacokinetics, In-
troduction, THE MERCK MANUALS, http://www.merck.com/mmpe/sec20/ 
ch303/ch303a.html (last visited Mar. 1, 2011). 
 21 See KEITH J. HARRISON, BIOSIMILARS INDIA 2009: MAPPING OUT THE LATEST 
DEVELOPMENTS IN EUROPEAN AND U.S. BIOSIMILAR REGULATION—ACHIEVING COST-
EFFECTIVE COMPLIANCE 16–18 (Dec. 2, 2009), available at 
http://www.crowell.com/documents/Mapping-Out-Latest-Developments-European-
And%20US%20Biosimilar%20Regulation-Achieving-Cost-Effective-Compliance.pdf 
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Barack Obama signed into law the Biologics Price Competition and 
Innovation Act of 2009 (BPCIA).
22
  The BPCIA forms part of the 
much-debated health care reform bill known as the Patient Protec-
tion and Affordable Care Act.
23
  With the enactment of the BPCIA, 
manufacturers of follow-on biologics will be able to file abbreviated 
applications for FDA approval for follow-on biologics.
24
  With this leg-
islation, Congress seeks to provide sufficient protection for innovator 
firms that have created biological products while simultaneously fos-
tering robust competition from follow-on competitors.
25
  Follow-on 
biologic applicants will aim to ensure that their products meet the 
FDA’s criteria for biosimilarity to the corresponding reference prod-
ucts yet remain different enough, either in composition or method of 
manufacture, so as to avoid infringing any of the patents covering the 
reference products.  According to the Congressional Budget Office, 
the legislation is expected to save the federal government approx-
imately $7 billion over the next decade in drug costs.
26
 
Most of the policy debate surrounding the BPCIA concerned the 
appropriate period, if any, of data exclusivity, meaning the period of 
time that an innovator firm’s pre-clinical and clinical data cannot be 
 
(outlining the protracted debate in the United States regarding the development of 
an abbreviated approval pathway for follow-on biologics). 
 22 Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §§ 7001–03, 
124 Stat. 119, 804–21 (2010) [hereinafter BPCIA]; Nathan Beaver et al., Update—
United States Enacts Approval Pathway for Biosimilars, MONDAQ BUSINESS BRIEFING, Apr. 
15, 2010.   
 23 Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 
(2010) (codified in scattered sections of 21 U.S.C., 35 U.S.C., and 42 U.S.C.). 
 24 The FDA defines an abbreviated application as “one that relies, to at least some 
extent, on the Agency’s conclusions regarding the safety and effectiveness (or safety, 
purity, and potency) of an approved product and also contains additional data ne-
cessary, other than the underlying clinical data supporting the approved product, to 
establish that the follow-on product is safe and effective.”  Safe and Affordable Biotech 
Drugs—The Need for a Generic Pathway: Hearing Before the H. Comm. on Oversight and Gov-
ernment Reform, 110th Cong. 5 (2007) (statement of Janet Woodcock, M.D., Deputy 
Commissioner, Chief Medical Officer, U.S. Food & Drug Admin.), available at 
http://www.hhs.gov/asl/testify/2007/04/t20070326a.html.  The BPCIA defines the 
term “biological product,” also known as a biologic or biopharmaceutical, as “a virus, 
therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, 
allergenic product, protein (except any chemically synthesized polypeptide), or ana-
logous product, or arsphenamine or derivative of arsphenamine (or any other triva-
lent organic arsenic compound), applicable to the prevention, treatment, or cure of 
a disease or condition of human beings.”  BPCIA § 7002(b)(1) (amending 42 U.S.C. 
§ 262(i) (2006)).   
 25 See Doug Trapp, Health Reform Law Gives Biologic Drugs 12-Year Exclusivity, 
AMEDNEWS.COM, Apr. 12, 2010, http://www.ama-assn.org/amednews/ 
2010/04/12/gvsa0412.htm. 
 26 Id. 
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used by a follow-on competitor.
27
  This issue did not arise in the EU 
because manufacturers of innovative biologics enjoy the same exclu-
sivity period as manufacturers of innovative chemical pharmaceuti-
cals.
28
  Now that it has enacted the BPCIA, the United States can look 
to the EU to determine the salient regulatory and policy issues that 
have come to the fore in that region during the last several years, af-
ter its enactment of an abbreviated approval pathway for biologics. 
Currently, the EU is grappling with the following six questions: 
(1) how to assess comparability of the reference and follow-on biolog-
ic products; (2) whether to designate a biologic as interchangeable 
with the reference product; (3) the appropriate levels of immunoge-
nicity testing, pharmacovigilance, and risk assessment for biosimilars; 
(4) the propriety of giving a follow-on biologic the same name as the 
reference product; (5) the approval of a biosimilar drug for indica-
tions for which it has not been evaluated in clinical trials, based on 
extrapolation of data from the reference product; and (6) potential 
extensions to the term of data exclusivity for biosimilars.  This Article 
will consider how the EU is dealing with these challenges with a view 
toward applying these lessons to the United States.  A full considera-
tion of these questions requires an understanding of the recently 
enacted BPCIA, as well as the EU legislative approval pathway for bio-
similars. 
II. THE BIOLOGICS PRICE COMPETITION AND INNOVATION  
ACT OF 2009 
A. The Follow-On Biologic Application and Approval Process  
Under the BPCIA 
The BPCIA provides that a follow-on biologic may be approved 
by the Secretary of the U.S. Department of Health and Human Ser-
vices (“the Secretary”)
29
 if it is “biosimilar” to the reference product.
30
  
 
 27 See e.g., Safe and Affordable Biotech Drugs—The Need for a Generic Pathway: Hearing 
Before the H. Comm. on Oversight and Government Reform, 110th Cong. 174–75 (2007) 
(statement of Henry G. Grabowski, Ph.D.), available at 
http://docs.govdoc.org/us/legi/house/cogr/hearings/HHRG-110-0043.pdf (testify-
ing, during Congressional hearings regarding an earlier draft biologics bill, in favor 
of a data exclusivity period for innovator biologics of at least ten years, akin to that of 
the EU) [hereinafter Grabowski Testimony]; Gitter, supra note 4, at 613–16 (describ-
ing the debate among industry representatives, legislators, and academics regarding 
data exclusivity for innovator biologics and advocating for ten to twelve years of data 
exclusivity).    
 28 See infra notes 42–45 and accompanying text. 
 29 42 U.S.C. § 262(k)(3) (Supp. IV 2010). 
 30 § 262(k)(2)(A)(i)(I). 
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Biosimilarity is defined to mean “that the biological product is highly 
similar to the reference product notwithstanding minor differences 
in clinically inactive components” and “there are no clinically mea-
ningful differences between the biological product and the reference 
product in terms of the safety, purity, and potency of the product.”
31
  
To assess biosimilarity, the FDA will determine, among other things, 
whether: (1) the follow-on product is “highly similar” to the reference 
product based on data from analytical, animal, and clinical studies; 
(2) the two products have the same mechanism of action, to the ex-
tent such mechanism is known; and (3) the conditions of use in the 
labeling for the proposed biological product have been previously 
approved for the reference product; and (4) the route of administra-
tion, dosage form, and strength of the two products are the same.
32
  
The BPCIA also provides that the Secretary “may determine, in the 
Secretary’s discretion, that any of these elements [considered for a 
showing of biosimilarity] is unnecessary.”
33
 
An applicant may also include in its application information 
demonstrating that its biological product meets a higher standard, 
namely, interchangeability.
34
  For a follow-on biologic to be deemed 
interchangeable, the applicant must demonstrate that the biological 
product is biosimilar to the reference product and “can be expected 
to produce the same clinical result as the reference product in any 
given patient.”
35
  Interchangeable products can then be substituted by 
a pharmacy without physician approval.
36
  With the enactment of the 
BPCIA, the FDA will issue guidance, after the requisite notice and 
comment period, for follow-on firms seeking to achieve designations 
of biosimilarity and interchangeability.
37
 
 
 31 § 262(i)(2)(B). 
 32 § 262(k)(2)(A)(i)(I)–(IV). 
 33 § 262(k)(2)(A)(ii). 
 34 § 262(k)(2)(B). 
 35 42 U.S.C. § 262(k)(2)(B)(4) (Supp. IV 2010).  Furthermore, if a biological 
product “is administered more than once to an individual,” it will be deemed inter-
changeable only if “the risk in terms of safety and diminished efficacy of alternating 
or switching between the use of the biological and the reference product is not 
greater than the risk of using the reference product without such alternation or 
switch.”  Id. 
 36 § 262(i)(3). 
 37 § 262(k)(8). 
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B. Exclusivity Provisions for Reference Biologics Pursuant to the 
BPCIA 
The thorniest issue relating to the enactment of the BPCIA in-
volved the length of the statutory exclusivity period for reference bi-
ologics.  Pursuant to the HWA, which provides an abbreviated ap-
proval pathway for traditional chemical pharmaceuticals,
38
 and upon 
which the BPCIA is modeled,
39
 there are two types of exclusivity: mar-
ket exclusivity and data exclusivity.  Market exclusivity is defined as “a 
period of time during which the FDA affords an approved drug pro-
tection from competing applications for marketing approval.”
40
  Un-
der the HWA, the marketing exclusivity provision precludes the FDA 
from approving any abbreviated new drug application for a generic 
drug for five years from the date the FDA approved the correspond-
ing reference drug, if that reference drug is a new chemical entity.
41
 
While the terms market exclusivity and data exclusivity are often 
considered synonymous under the HWA,
42
 in the EU these terms are 
usually parsed more precisely.  Throughout the EU, all branded me-
dicinal products, including traditional chemical pharmaceuticals and 
biologics, are governed by the 8+2+1 rule.
43
  The innovator may re-
ceive up to eight years of data exclusivity, which means that a follow-
on firm may not even submit a biosimilar application that relies on an 
innovator firm’s data until eight years after the EMA’s authorization 
 
 38 Pub. L. No. 98-417, 98 Stat. 1585 (1984) (amending the Federal Food, Drug, 
and Cosmetic Act Pub. L. 75-717, § 505(j), 52 Stat. 1040 (1938), codified at 21 U.S.C. 
§ 355(j) (2006)).  Under the HWA, generic drug manufacturers are typically not re-
quired to submit pre-clinical and clinical data along with their abbreviated new drug 
applications, thereby by-passing the significant expenses associated with developing 
new pharmaceuticals.  See id.  In order to take advantage of this abbreviated pathway, 
the generic manufacturer must prove that the generic version of the drug contains 
the same active ingredient as the original, demonstrates bioequivalence to the origi-
nal, and is manufactured according to appropriate practices.  See 21 U.S.C. § 
355(j)(2)(A). 
 39 See Ralph A. Loren & Thomas H. Wintner, New Law! The Biologics Price Competi-
tion and Innovation Act of 2009, MARTINDALE.COM (Apr. 12, 2010), 
http://www.martindale.com/health-care-law/article_Edwards-Angell-Palmer-Dodge-
LLP_976250.htm. 
 40 WENDY H. SCHACHT & JOHN R. THOMAS, CONG. RESEARCH SERV., RL 33901, 
FOLLOW-ON BIOLOGICS: INTELLECTUAL PROPERTY AND INNOVATION ISSUES 13 (2009), 
available at http://www.ipmall.info/hosted_resources/crs/RL33901_090320.pdf. 
 41 21 U.S.C. § 355(j)(5)(F)(ii) (2006); 21 C.F.R. § 314.108(b)(2) (2010).  The 
period of market exclusivity is three years after the approval date if the innovator 
drug is not a new chemical entity.  § 355(j)(5)(F)(iii).   
 42 See Grabowski Testimony, supra note 27, at 172–74. 
 43 See Joyce Wing Yan Tam, Biologics Revolution: The Intersection of Biotechnology, Pa-
tent Law, and Pharmaceutical Regulation, 98 GEO. L. J. 535, 554 (2010). 
GITTER.DOCX (DO NOT DELETE) 4/12/2011  8:37 AM 
2011] THE EUROPEAN UNION EXPERIENCE 567 
of the reference product.
44
  What is more, the branded firm receives 
an additional two years of purely market exclusivity, meaning that the 
follow-on firm may not market the biosimilar product until ten years 
(i.e., 8 + 2) have elapsed from the EMA’s authorization of the refer-
ence product.
45
  In addition, the period of exclusivity can be ex-
tended to a maximum of eleven years (8 + 2 + 1) if, during the first 
eight years of data exclusivity, the holder of the reference product 
“obtains an authorisation for new therapeutic indication(s) which 
bring(s) significant clinical benefits in comparison with existing ther-
apies.”
46
 
In discussions regarding the BPCIA, innovator firms, 
represented by the Biotechnology Industry Organization trade group, 
sought an exclusivity period totaling fourteen years, while the Gener-
ic Pharmaceutical Association sought much less.
47
  Indeed, one draft 
version of the legislation provided for no market exclusivity period 
whatsoever for the reference drug.
48
  Meanwhile, scholars and policy 
makers supported varying periods of exclusivity.
49
 
The BPCIA ultimately established a four-year data exclusivity pe-
riod to run concurrently with a twelve-year market exclusivity period 
for reference biologic drugs.
50
  A follow-on biologic application may 
not be submitted until four years after the FDA’s authorization of the 
reference product, and a follow-on biologic application may not be 
 
 44 See id. 
 45 Follow-On Biologics: Hearing Before the S. Comm. on Health, Education, Labor and 
Pensions, 110th Cong. 3 (2007) (statement of Nicolas Rossignol, Administrator, Eu-
ropean Commission, Pharmacuticals Unit), available at http://help.senate.gov/imo/ 
media/doc/Rossignol.pdf [hereinafter Rossignol Testimony]; see also Elisabeth Ber-
thet-Maillols, Biosimilar EPO: The Reasons to Be Confident, 6 J. GENERIC MEDS. 111, 114 
(2009).     
 46 Rossignol Testimony, supra note 45, at 3.   
 47 Trapp, supra note 25. 
 48 See Gitter, supra note 4, at 611–12. 
 49 See, e.g., Grabowski Testimony, supra note 27, at 174 (“A ten year exclusivity pe-
riod, like that currently exists in Europe, would help balance innovation incentives 
and price competition when instituting a new regulatory pathway for biologicals.”); 
David E. Adelman & Christopher M. Holman, Misplaced Fears in the Legislative Battle 
Over Affordable Biotech Drugs, 50 IDEA 565, 565–70 (2010) (favoring a twelve-year data 
exclusivity period for biologics); Gitter, supra note 4, at 613–16. 
[A] data protection period of ten to twelve years, which would run 
concurrently with the patent term for the product, would provide pio-
neer firms with the assurance that they would earn a reasonable mono-
poly period in return for the time, money, and effort they expended in 
developing an innovator biologic product. 
Id. at 616. 
 50 42 U.S.C. § 262(k)(7)(A)–(B) (Supp. IV 2010). 
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approved by the FDA until twelve years after FDA authorization of the 
reference product.
51
  Thus, unlike the EU, which affords biologics the 
same data and marketing exclusivity periods as any other innovative 
drug,
52
 the United States has established a separate exclusivity period 
for biologics. 
C. Patent Infringement Issues Relating to the BPCIA 
Another salient feature of the BPCIA, which is markedly differ-
ent from the HWA, is the process by which a follow-on manufacturer 
can learn about the patents relating to the reference product.  With 
respect to traditional chemical drugs, once the FDA approves a new 
product, the agency publishes the drug name and related patent in-
formation in its Approved Drug Products with Therapeutic Equiva-
lence Evaluations, also known as the Orange Book.
53
  The HWA in-
cludes this provision in order to provide the public, including generic 
manufacturers of traditional chemical drugs, with information about 
patents held by innovator firms.
54
  Manufacturers of biologics, howev-
er, do not publish their patent information in the Orange Book.
55
  In 
order to provide manufacturers of follow-on biologics with informa-
tion about patents held by innovator firms, analogous to the informa-
tion enjoyed by manufacturers of generic drugs, the BPCIA requires a 
process of information exchange between the reference product 
sponsor, typically the patent holder or licensee, and the follow-on bi-
ologic applicant.
56
 
 
 51 Id.  In addition, an additional six months of exclusivity may be obtained for 
approved pediatric or rare disease indications.  § 262(m).  The BPCIA also provides 
exclusivity for the first interchangeable biological product.  § 262(k)(6).  In contrast, 
the EU does not afford any exclusivity to biosimilar products.  See CHU & PUGATCH, 
supra note 15, at 22. 
 52 See supra note 43 and accompanying text.  
 53 See 21 C.F.R. § 314.3(b) (2010).  The Approved Drug Products with Therapeu-
tic Equivalence Evaluations is commonly referred to as the Orange Book.  Orange 
Book: Approved Drug Products with Therapeutic Equivalence Evaluations, U.S. FOOD & 
DRUG ADMIN. http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm (last vi-
sited Jan. 29, 2011).  
 54 See Cynthia H. Zhang, Innovator vs. Generic: The Interplay of Patent Delisting and 
180-Day Market Exclusivity, 5 TRENDS IN BIO/PHARMACEUTICAL INDUSTRY 16, 17 (2009). 
 55 Tam Q. Dinh, Potential Pathways for Abbreviated Approval of Generic Biologics under 
Existing Law and Proposed Reforms to the Law, 62 FOOD & DRUG L.J. 77, 111 (2007) (stat-
ing that “a biologic approved under a BLA is not listed in the Orange Book”).    
 56 See Loren & Wintner, supra note 39.  For the details of this process, see 42 
U.S.C. § 262(l) (Supp. IV 2010). 
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III. THE EUROPEAN UNION LEGISLATIVE FRAMEWORK FOR BIOSIMILARS 
The EU legislative framework for abbreviated approval of biosi-
milars proves instructive in light of the similarities between EU and 
U.S. pharmaceutical approval processes.  In both regions, all bio-
technological products, including biosimilars, undergo rigorous re-
view and a centralized approval process.
57
  Moreover, both regions of-
fer patent protection for twenty years from the filing of the 
application as well as a strong commitment to intellectual property 
rights and the implementation of an exclusivity period for firms that 
create new products.
58
 
In 2005 the EU successfully established a comprehensive regula-
tory pathway for biosimilar products.
59
  It was the first region in the 
world to do so.
60
  Branded biologics must proceed through a centra-
lized regulatory process, mediated by the EMA, which is effective 
throughout all twenty-seven EU Member States.
61
  In contrast, tradi-
tional chemical pharmaceuticals may submit either to the centralized 
authorization process or, alternatively, to national authorization pro-
cedures.
62
  In its role as the agency evaluating all biologics, the EMA 
and its scientific Committee for Medicinal Products for Human Use 
(CHMP)
63
 developed several guidance documents to create detailed 
 
 57 See LINDA R. HORTON, THE EUROPEAN EXPERIENCE WITH FOLLOW-ON BIOLOGICS 
LEGISLATION 4 (2008), available at http://www.ftc.gov/bc/workshops/hcbio/docs/ 
fob/lhortonsv.pdf.  
 58 Id.  It should also be noted that the U.S. and EU differ in some significant 
ways.  For example, each of the twenty-seven EU Member States has its own health-
care system and exercises self-determination with respect to pharmaceutical reim-
bursement, pricing, and substitutability.  Id.  Moreover, in the EU, national differ-
ences persist in the patent systems.  Id. 
 59 See Council Directive 2004/27, 2004 O.J. (L 136) 47, 34–57 (EC) (amending 
Directive 2001/83 on the Community Code Relating to Medicinal Products for Hu-
man Use); Commission Regulation 726/2004, 2004 O.J. (L 136) 1–33 (EC). 
 60 See Schellekens & Moors, supra note 4, at 30.   
 61 Central Authorisation of Medicines, EUR. MEDS. AGENCY [hereinafter EMA],  
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_
content_000109.jsp&murl=menus/about_us/about_us.jsp&mid=WC0b01ac 
0580028a47&jsenabled=true (last visited Mar. 2, 2011); see also Simoens, supra note 2, 
at 213 (noting that the EMA assesses biopharmaceuticals through the centralized 
procedure). 
 62 EMA, supra note 61. 
 63 See Liang, supra note 17, at 398–99.  For human drugs, once a company submits 
a marketing authorization application to the EMA as part of the centralized process, 
the CHMP, which is the scientific arm of the EMA, evaluates the product.  Id.  If the 
CHMP concludes that the product meets the requisite quality, safety, and efficacy 
standards, CHMP sends this recommendation to the European Commission, which 
may, in its discretion, issue a market authorization valid throughout the EU.  Id.  The 
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criteria for approval.
64
  The three essential requirements of the EMA 
CHMP guidelines for biosimilars are (1) the provision of the requisite 
 
CHMP is also charged with some post-authorization responsibilities, such as review of 
modifications and extensions of the existing marketing authorization.  Id. 
 64 See Schellekens & Moors, supra note 4, at 28.  The first EMA/CHMP guideline 
regarding biologics, the Guideline on Similar Biological Medical Products, which came 
into effect in October 2005, aimed “to introduce the concept of similar biological 
medicinal products; to outline the basic principles to be applied; and to provide ap-
plicants with a ‘user guide’, showing where to find relevant scientific information in 
the various CHMP guidelines in order to substantiate the claim of similarity.”  Eur. 
Meds. Agency [EMA], Guideline of Similar Biological Medicinal Products, at 3, EMEA 
Doc. No. CHMP/437/04 (Oct. 30, 2005), available at http://www.ema.europa.eu/ 
docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf 
[hereinafter EMA, EMEA/CHMP/437/04].  In June 2006, two additional 
EMA/CHMP guidelines came into effect.  The Guideline on Similar Biological Medicinal 
Products Containing Biotechnology-Derived Proteins as Active Substances: Quality Issues aims 
to establish “the quality requirements for a biological medicinal product claiming to 
be similar to another one already marketed.”  EMA, Guideline on Similar Biological Me-
dicinal Products Containing Biotechnology-Derived Proteins as Active Substances: Quality Is-
sues, at 3, EMEA Doc. No. CHMP/BWP/49348/2005 (Feb. 22, 2006), available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2
009/09/WC500003953.pdf [hereinafter EMA, EMEA/CHMP/49348/2005].  This 
document addresses requirements pertaining to biosimilars with respect to manufac-
turing processes, analytical methods to assess comparability, factors to consider when 
choosing a reference product, and physicochemical and biological characterization 
of biosimilars.  Id.  The Guideline on Similar Biological Medicinal Products Containing Bio-
technology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues, which also 
took effect in June 2006, addresses pre-clinical requirements for biosimilars, mainly 
pharmaco-toxological assessment, along with clinical requirements, namely, pharma-
cokinetic, pharmacodynamic, efficacy, and safety studies, with an emphasis on eva-
luating the immunogenicity of biosimilars.  EMA, Guideline on Similar Biological Medi-
cinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical 
and Clinical Issues, at 3, EMEA Doc. No. CHMP/BWP/42832/2005 (Feb. 22, 2006), 
available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ 
guideline/2009/09/WC500003920.pdf [hereinafter EMA, EMEA/CHMP/BWP/ 
42832/2005].  In April 2008, the Guideline on Immunogenicity Assessment of Biotechnolo-
gy-Derived Therapeutic Proteins came into effect.  EMA, Guideline on Immunogenicity As-
sessment of Biotechnology-Derived Therapeutic Proteins, at 1, EMEA Doc. No. 
CHMP/BWP/14327/2006 (Dec. 13, 2007), available at http://www.ema.europa.eu/ 
docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf.  
This document considers the immunogenic issues that biopharmaceutical companies 
must address for approval of a biosimilar product or when a manufacturing change 
occurs.  Id. at 4.  These include factors that affect immunogenicity and the potential 
consequences of it; the development, design, and interpretation of pre-clinical and 
clinical assays to evaluate the immunogenic potency of a product and its comparabili-
ty to other products; and the implementation of a risk management plan.  See id. at 
7–13.   
Finally, the EMA/CHMP has also adopted six product-specific guidelines, relat-
ing to the development of biosimilars containing recombinant erythropoietin; re-
combinant interferon alpha; low-molecular-weight-heparin; somatropin; human insu-
lin; and granulocyte colony-stimulating factor.  E-mail from Anna Nagielska, 
Document and Information Services, European Medicines Agency, to author (July 
29, 2010, 10:13 EST) (on file with author).  These documents set forth pre-clinical 
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pre-clinical and clinical data; (2) a comparability exercise to show 
biosimilarity in quality, efficacy, and safety; and (3) product-specific 
pharmacovigilance and risk management plans to monitor potential 
immunogenicity.
65
 
With respect to the first requirement, the EMA’s regulatory 
framework for biosimilars mandates clinical trial data in order to 
 
and clinical data requirements for marketing approval, describing the size of the 
clinical trials required and the best means of demonstrating equivalence for each 
product in comparison to the reference product.  See EMA, Guideline on Clinical and 
Non-Clinical Development of Similar Biological Medicinal Products Containing Recombinant 
Erythropoietins (Revision), at 3, EMEA Doc. No. CHMP/BMWP/301636/2008 (Mar. 18. 
2010), available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2
010/04/WC500089474.pdf (Mar. 18, 2010) [hereinafter EMA, 
EMEA/CHMP/BMWP/301636/2008]; EMA, Reflection Paper on Non-Clinical and Clin-
ical Development of Similar Medicinal Products Containing Recombinant Interferon Alpha, at 
3, EMEA Doc. No. CHMP/BMWP/118264/07 (Apr. 23, 2009), available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2
009/09/WC500003930.pdf [hereinafter EMA, EMEA/CHMP/BMWP/ 
301636/2008]; EMA, Guideline on Clinical and Non-Clinical Development of Similar Bio-
logical Medicinal Products Containing Low-Molecular-Weight-Heparins, at 3, EMEA Doc. 
No. CHMP/BMWP/118264/07 (Mar. 19, 2009), available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline 
/2009/09/WC500003927.pdf; EMA, Annex to Guideline on Similar Biological Medicinal 
Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and 
Clinical Issues: Guidance on Similar Medicinal Products Containing Somatropin, at 3, EMEA 
Doc. No. CHMP/94528/2005 (Feb. 22, 2006), available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2
009/09/WC500003956.pdf [hereinafter EMA, EMEA/CHMP/94528/2005]; EMA, 
Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-
Derived Proteins as Active Substance: Non-Clinical and Clinical Issues: Guidance on Similar 
Medicinal Products Containing Recombinant Human Soluble Insulin, at 3, EMEA Doc. No. 
CHMP/32775/05 (Feb. 22, 2006) , available at http://www.ema.europa.eu/docs/ 
en_GB/document_library/Scientific_guideline/2009/09/WC500003957.pdf [herei-
nafter EMA, EMEA/CHMP/32775/05]; EMA, Annex to Guideline on Similar Biological 
Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-
Clinical and Clinical Issues: Guidance on Similar Medicinal Products Containing Recombi-
nant Granulocyte-Colony Stimulating Factor, at 3, EMEA Doc. No. CHMP/31329/2005 
(Feb. 22, 2006), available at http://www.ema.europa.eu/docs/en_GB/document_ 
library/Scientific_guideline/2009/09/WC500003955.pdf [hereinafter EMA, 
EMEA/CHMP/31329/2005].  
 65 See Kadriye Ciftci, Biosimilars or Follow-on Biologics: Scientific and Regulatory Con-
siderations, INCON INSIGHT, Mar. 2010, http://www.iconplc.com/icon-files/insight-
newsletter/Spring10/ biosimilars.html (“Regulatory authorities agree that non-
clinical and clinical data are needed to demonstrate the safety and efficacy of a bio-
similar.  In addition, post-marketing surveillance and Risk Management Plans should 
be in place for the approval of biosimilar products.” (citations omitted)); Schelle-
kens, supra note 7, at i31 (describing the EMA’s requirements for pre-clinical and 
clinical data; a comparability analysis; and pharmacovigilance plans); Schellekens & 
Moors, supra note 4, at 30 (noting the EMA’s need for pre-clinical and clinical data 
and a comparability exercise in order to approve a biosimilar).  
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demonstrate that the follow-on products are effective and safe.
66
  The 
EMA takes a case-by-case approach, acknowledging that while “the 
concept of ‘a similar biological medicinal product’ is theoretically 
applicable to any biological medicinal product,” in practical terms, 
the success of an abbreviated approval pathway for biosimilars “will 
depend on the ability to characterise the product and therefore to 
demonstrate the similar nature of the concerned products.”
67
  The 
applicant “may not be required to repeat full safety and efficacy test-
ing, but the EMA retains the discretion to require the full array of 
pre-clinical and clinical data if the biologic’s structure is too complex 
to establish equivalence adequately.”
68
  For example, immunologicals, 
such as vaccines and allergens, are unlikely to be thoroughly charac-
terized at a molecular level and will more likely need to be consi-
dered on an ad hoc basis.
69
  Moreover, the EMA has issued six prod-
uct-specific guidelines that address specific requirements for pre-
clinical testing and clinical trials for recombinant erythropoietin, re-
combinant interferon alpha, low-molecular-weight-heparin, somatro-
pin, human insulin, and granulocyte colony-stimulating factor.
70
 
The second requirement of the EMA CHMP regulatory frame-
work is a comparability study in order to demonstrate that a particu-
lar follow-on biologic is similar to the reference product in terms of 
quality, safety, and efficacy.
71
  Indeed, neither the EU legislation 
creating an abbreviated approval pathway nor the EMA CHMP guide-
lines state a definition of a biosimilar other than that it is a protein 
product comparable in quality, safety, and efficacy to a reference 
product.
72
 
Because the EMA CHMP has not defined precisely the accepta-
ble level of differences between biosimilar and reference products in 
 
 66 See Schellekens & Moors, supra note 4, at 28. 
 67 EMA, EMEA/CHMP/437/04, supra note 64, at 3. 
 68 Wing Yan Tam, supra note 43, at 548 (citation omitted). 
 69 EMA, EMEA/CHMP/437/04, supra note 64, at 6.  As explained by one EMA 
scientist, pharmaceuticals can be arranged in terms of ascending order of complexity 
and difficulty of characterization as follows:  chemicals; recombinant DNA technolo-
gy; blood-derived; immunologicals, and advanced therapies.  SUZETTE KOX, THE 
BIOSIMILAR FRAMEWORK IN THE EUROPEAN UNION 16 (2009), available at 
http://www.egagenerics.com/doc/jga_symposium_2009-02-18_skox.pdf (citing Dr. 
John Purves of the EMA). 
 70 See supra note 64. 
 71 See EMA, EMEA/CHMP/437/04, supra note 64, at 3.  The reference product 
must itself have proceeded through the standard biological drug licensure process, 
not an abbreviated process.  Id.  Thus, one follow-on product cannot serve as a refer-
ence product for other follow-on biologics.  Id. 
 72 Schellekens & Moors, supra note 4, at 29. 
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terms of quality, safety, and efficacy, it is necessary to look to exam-
ples of biosimilar products for which the EMA CHMP permits use of 
the abbreviated approval pathway.  The EMA has permitted biosimi-
lars that have used completely different host cells, dissimilar formula-
tions, differences in the levels of impurities, and variability in the le-
vels of glycosolation.
73
  According to Huub Schellekens and Ellen 
Moors, while these variations “are known to have the potential to 
have a major effect on a product’s clinical efficacy and safety,” clinical 
studies of biosimilars tested thus far have nonetheless demonstrated 
that “these differences have not compromised efficacy or influenced 
the level of adverse drug reactions in humans compared with the 
brand product.”
74
 
The third EMA CHMP requirement for biosimilars is pharmaco-
vigilance, which the World Health Organization (WHO) defines as 
“the science and activities relating to the detection, assessment, un-
derstanding and prevention of adverse effects or any other medicine-
related problem” following the launch of a biological product on the 
market.
75
  Indeed, in the EU, post-marketing monitoring is even re-
quired for new, innovative biologics, in light of the clinically mea-
ningful differences between products and risk of immunogenicity.
76
  
As one expert noted, several factors, including the presence of im-
purities, structural modifications resulting from the manufacturing 
process or storage conditions, administration route, and patient cha-
racteristics, can all affect immunogenic potential and render it im-
possible to accurately predict immunogenicity in a patient.
77
  For bio-
 
 73 Id.  “[I]t is the glycosylation of some proteins, which refers to ‘the variable at-
tachment of small chains of sugars to the protein backbone,’ that renders glycosy-
lated proteins more complex than nonglycosylated ones.”  Gitter, supra note 4, at 560 
n.19 (quoting David M. Dudzinski, Reflections on Historical, Scientific, and Legal Issues 
Relevant to Designing Approval Pathways for Generic Versions of Recombinant Protein-Based 
Therapeutics and Monoclonal Antibodies, 60 FOOD & DRUG L.J. 143, 224 (2005)).   
 74 Schellekens & Moors, supra note 4, at 29.  Interestingly, Schellekens and Moors 
point out that the technology used to produce follow-on protein products is in many 
cases superior to that of the reference products because brand manufacturers some-
times continue to employ old technologies in light of the significant financial and 
regulatory drawbacks involved in updating their production processes.  Id. at 31; see 
infra note 126 and accompanying text. 
 75 WORLD HEALTH ORG., WHO POLICY PERSPECTIVES ON MEDICINES: 
PHARMACOVIGILANCE: ENSURING THE SAFE USE OF MEDICINES 1 (Oct. 2004), available at 
http://apps.who.int/medicinedocs/pdf/s6164e/s6164e.pdf; see also Simoens, supra 
note 2, at 215 (“EMEA guidelines also impose pharmacovigilance programmes to fol-
low up safety and efficacy of biosimilars once approval has been gained.”). 
 76 See Harrison, supra note 21, at 3 (“Biosimilars are required to undergo post-
marketing monitoring just like new innovative biologies.”).  
 77 See Ciftci, supra note 65.   
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similars in particular, pharmacovigilance is crucial because limited 
clinical data about safety risks tends to be available at the time of 
marketing authorization by the EMA due to the abbreviated approval 
pathway enjoyed by biosimilars.
78
 
The EU established a pharmacovigilance program for all phar-
maceuticals, chemical and biologic,
79
 which includes several elements.  
First, a health-care professional can spontaneously report suspected 
adverse reactions to pharmaceuticals via the EudraVigilance net-
work.
80
  Second, the EMA often requires drug manufacturers, as part 
of the approval process, to develop and implement pharmacovigil-
ance plans tailored to their particular products.
81
  Such plans may in-
clude patient registries, along with retrospective and prospective ob-
servational and pharmacoepidemiological studies.
82
  For instance, in 
2003 the EMA approved the monoclonal antibody infliximab for the 
treatment of a particular inflammatory disease, ankylosing spondyli-
tis, subject to the condition that the manufacturer conduct a follow-
up clinical study to investigate the safety and efficacy of infliximab 
over a period of two years.
83
 
In addition to submitting a pharmacovigilance plan, any appli-
cant for market authorization for a new active substance, biosimilars 
included, must provide to the EMA a risk management plan (RMP),
84
 
which details “the actions and the surveillance that is undertaken to 
identify and manage potential safety risks.”
85
  A RMP aims to be more 
proactive in risk management than a pharmacovigilance plan.
86
  For 
example, to minimize the risk of infections following administration 
of natalizumab, a monoclonal antibody for relapsing multiple sclero-
sis,
87
 the risk management plan imposed “a clear-cut definition of the 
 
 78 See Mellstedt et al., supra note 1, at 415. 
 79 Volume 9A of The Rules Governing Medicinal Products in the European Un-
ion: Guidelines on Pharmacovigilance for Medicinal Products for Human Use (EU), 
Sept. 2008 [hereinafter Volume 9A], available at http://ec.europa.eu/enterprise/ 
sectors/pharmaceuticals/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf. 
 80 See Mellstedt et al., supra note 1, at 416. 
 81 See id. 
 82 See id. 
 83 See Simoens, supra note 2, at 213. 
 84 Volume 9A, supra note 79, at 38; see also Berthet-Maillols, supra note 45, at 112; 
Thijs Giezen et al., Pharmacovigilance of Biosimilars from a Regulatory Point of View: Is 
There a Need for a Specific Approach?, 21 INT’L J. RISK & SAFETY IN MED. 53, 55 (2009). 
 85 See Simoens, supra note 2, at 213. 
 86 See Giezen et al, supra note 84, at 55.  
 87 Questions and Answers on Natalizumab, U.S. FOOD & DRUG ADMIN., Nov. 23, 2004, 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatient
sandProviders/ucm107203.htm. 
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target population, the requirement for established multiple sclerosis, 
an escape rule for non-responders, the administration in specialised 
centres by experienced physicians only, clear contraindications, a pa-
tient alert card, and an educational programme for physicians.”
88
 
IV. REGULATORY AND POLICY ISSUES RAISED BY AN ABBREVIATED 
APPROVAL PATHWAY FOR BIOLOGICS IN LIGHT OF THE EU EXPERIENCE 
For over five years the EU has relied on the abbreviated biosimi-
lar pathway described above, which rests upon three essential re-
quirements: (1) the provision of the requisite pre-clinical and clinical 
data; (2) a comparability exercise to show biosimilarity in quality, ef-
ficacy, and safety; and (3) product-specific pharmacovigilance and 
risk management plans to monitor potential immunogenicity.  Dur-
ing this time, the major regulatory and policy issues that have arisen 
in that region include (1) how to assess comparability of the refer-
ence and follow-on biologic products; (2) whether to designate a bi-
ologic as interchangeable with the reference product; (3) the appro-
priate levels of immunogenicity testing, pharmacovigilance and risk 
assessment for biosimilars; (4) the propriety of giving a follow-on bi-
ologic the same name as the reference product; (5) the approval of a 
biosimilar drug for indications for which it has not been evaluated in 
clinical trials, based on extrapolation of data from the reference 
product; and (6) potential extensions to the term of data exclusivity 
for biosimilars.  The FDA will need to consider each of these issues in 
developing guidance for manufacturers of follow-on biologics. 
A. The Challenge of Assessing Comparability 
The FDA must decide how to implement the “biosimilarity” de-
signation, which requires that a product be “highly similar” to the 
reference product “notwithstanding minor differences in clinically 
inactive components.”
89
  Among the questions the FDA must resolve 
is how much and what form of data will be required, including how 
much animal data and how much clinical data, in light of the agree-
ment among most regulatory authorities that both pre-clinical and 
clinical data are needed to demonstrate the safety and efficacy of a 
biosimilar.
90
  It is instructive, then, to analyze how the EU handles the 
issue of comparability for biosimilars.  Indeed, some commentators 
 
 88 Simoens, supra note 2, at 213 (citations omitted). 
 89 42 U.S.C. § 262(k)(2)(A) (Supp. IV 2010); see supra notes 29–32 and accompa-
nying text. 
 90 See Ciftci, supra note 65 (citation omitted). 
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have noted that the EMA and the FDA have been working closely 
with one another, and FDA guidelines are likely to be based in large 
measure on the EMA’s guidelines.
91
 
While EMA guidelines indicate that “official data,” such as 
pharmacopoeial monographs or other published scientific data, will 
be used initially to assess comparability, prior published information 
alone will not be adequate for approval, and “an extensive compara-
bility exercise will be required” in order to demonstrate that the ap-
plicant drug and reference product have similar profiles in quality, 
safety, and efficacy.
92
  The comparability exercise is typically per-
formed through a “stepwise procedure” that begins with pharmaco-
kinetic
93
 and pharmacodynamic
94
 studies, followed by clinical safety 
and efficacy trials, or, in certain cases, pharmacokinet-
ic/pharmacodynamic studies for demonstrating clinical comparabili-
ty.
95
  The EMA emphasizes that pharmacokinetic studies “should not 
necessarily mimic” new drug application testing but instead, should 
focus on elucidating differences between the reference and biosimi-
lar molecules.
96
  For example, pharmacokinetic studies should ex-
plore differences in drug and reference biologic elimination from 
the body, and pharmacodynamic studies should compare the refer-
ence and biosimilar products in a population where possible clinical 
differences in the two products can best be observed.
97
  As explained 
by the EMA, “it is not expected that the quality attributes in the simi-
lar biological and reference medicinal products will be identical,” 
and it is expected that there will be “minor structural differences in 
the active substance, such as variability in post-translational modifica-
tions.”
98
  Thus, different amounts of pre-clinical and clinical data will 
be required on a case-by-case basis in order to ascertain the safety and 
efficacy of biosimilars.
99
 
 
 91 See Peter Gaskin, Latest EU Guidelines Dissected, PHARMACEUTICAL TECH. EUR., 
Aug, 2010, at 8, available at http://www.pharmtech.com/ptedigital0810. 
 92 EMA, EMEA/CHMP/49348/2005, supra note 64, at 3. 
 93 See supra note 20 (defining “pharmacokinetics”). 
 94 Pharmacodynamics is sometimes described as “what a drug does to the body” 
and “involves receptor binding, postreceptor effects, and chemical interactions.”  
THE MERCK MANUALS, supra note 20.  Pharmacodynamics, coupled with pharmacoki-
netics, elucidates a drug’s effects on a person.  Id. 
 95 EMA, EMEA/CHMP/BWP/42832/2005, supra note 64, at 5. 
 96 Id. 
 97 Id.  
 98 EMA, EMEA/CHMP/49348/2005, supra note 64, at 4. 
 99 Id. at 4–5.  The EMA states that the “differences between the impurity profiles 
of the similar biological medicinal product and the reference medicinal product 
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In terms of pre-clinical testing, the EMA guidelines indicate that 
pre-clinical testing may be abbreviated, although some testing must 
be performed.  Pre-clinical testing should be truly comparative in na-
ture and “designed to detect differences in response between the sim-
ilar biological product and the reference medicinal product and not 
just the response per se.”
100
  Such testing should include pharmacoki-
netic and pharmacodynamic studies.
101
  Further, both in vitro and in 
vivo testing should be performed.
102
  The EMA guidelines state that 
other “routine toxicological studies such as safety pharmacology, re-
production toxicology, mutagenicity and carcinogenicity studies” are 
not “normally” required.
103
  Ultimately, the biosimilar applicant must 
justify its choice of pre-clinical studies performed and omitted.
104
 
With respect to clinical testing, the EMA states that the require-
ments depend upon “the existing knowledge” about the reference 
product and its therapeutic indication.
105
  Although the EMA ac-
knowledges that manufacturing processes may change during the bi-
ologic development process, it recommends generating clinical data 
for comparability purposes with the biosimilar using the final manu-
facturing process and suggests that additional clinical testing re-
quirements may be imposed if this recommendation is not fulfilled.
106
  
Just as for pre-clinical testing, justification of pharmacokinetic and 
pharmacodynamic testing approaches is required.
107
 
Generally, clinical trials to demonstrate clinical comparability 
and efficacy should be performed once the necessary pharmacokinet-
ic and pharmacodynamic assessments are complete.
108
  But an abbre-
viated process may be available, and comparative pharmacokinetic 
and pharmacodynamic testing between the biosimilar and the refer-
ence biologic may be substituted for clinical studies if certain criteria 
are met, all of which relate to the extent to which the reference bi-
 
should be justified and would be considered on a case-by-case basis” and that “differ-
ences in impurity profiles and significant differences in product related substances 
may have consequences with regard to the amount of non-clinical and clinical data 
which may be required.”  Id. 
 100 EMA, EMEA/CHMP/BWP/42832/2005, supra note 64, at 4. 
 101 Id. at 4–5.  
 102 Id. at 4. 
 103 Id. 
 104 Id.  
 105 Id. at 5. 
 106 EMA, EMEA/CHMP/BWP/42832/2005, supra note 64, at 5. 
 107 Id.  
 108 Id. 
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ologic’s characteristics are well known.
109
  In addition, product-
specific guidelines are available for particular product classes of bio-
similars.
110
 
In order to assess how the EMA has implemented the compara-
bility analysis with respect to a specific biosimilar, it is instructive to 
consider erythropoietin, which is used to treat anemia in patients 
with chronic kidney disease as well as patients receiving chemothera-
py treatment for cancer.
111
  Erythropoietin is recognized as one of the 
most difficult products for which to develop a biosimilar.
112
  The EMA 
guidelines for erythropoietin state that comparability studies of clini-
cal efficacy between the reference and biosimilar products should be 
performed in patients with anemia due to chronic renal disease.
113
  In 
addition, the pharmacokinetic properties of the reference and biosi-
milar products should be compared for both routes of administration 
applied for, namely, intravenous and subcutaneous.
114
  Current EMA 
guidelines also allow for extrapolation
115
 of safety and efficacy data 
from patients with renal anemia to other indications of the reference 
product with the same route of administration if the extrapolation 
can be appropriately justified.
116
 
It should be noted that while the EMA has approved fourteen of 
the eighteen biosimilar applications submitted to it, it has rejected 
one, and three applications for other biosimilars have been with-
drawn by their manufacturers because of the likelihood that they 
would not be approved due to lack of comparability.
117
  In 2006, the 
EMA rejected the application for marketing approval for Alpheon, a 
 
 109 Id. at 5–6. 
 110 See supra note 64. 
 111 See Mellstedt et al., supra note 1, at 414. 
 112 See id. at 415. 
 113 See id. 
 114 EMA, EMEA/CHMP/BMWP/301636/2008, supra note 64, at 5. 
 115 Extrapolation “involves the approval of a drug for indications for which it has 
not been evaluated in clinical trials.”  Mellstedt et al., supra note 1, at 417.  The EMA 
has generally accepted the concept of data extrapolation for biosimilars “with the 
appropriate justification.”  Id.   
 116 EMA, EMEA/CHMP/BMWP/301636/2008, supra note 64, at 8. 
 117 E-mail from Anna Nagielska, Document and Information Services, European 
Medicines Agency, to author (July 23, 2010, 06:47 EST) (on file with author); see also 
EMA, Questions and Answers on the Withdrawal of the Marketing Authorisation Application 
for Insulin Human Rapid Marvel, Insulin Human Long Marvel, Insulin Human 30/70 Mix 
Marvel, at 1, EMEA Doc. No. 4193/2008 (Jan. 24, 2008), available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/1
1/WC500015341.pdf. 
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biosimilar version of a branded interferon product.
118
  The manufac-
turer of Alpheon submitted pre-clinical data on the biosimilar and al-
so conducted a randomized controlled trial in 455 patients with he-
patitis C to demonstrate comparability with the reference product.
119
  
The EMA rejected the application due to, among other factors, quali-
ty and clinical differences between Alpheon and the reference prod-
uct, inadequate data on the stability of the active substance, inade-
quate validation of the process for the finished product, and 
insufficient validation of immunogenicity testing.
120
 
While the EMA process for approving biosimilars is generally 
recognized as a success, Schellekens and Moors question the EMA 
CHMP requirement for comparability studies, as a complement to 
the necessary clinical data.
121
  According to Schellekens and Moors, 
“the merits and/or added value of the comparability exercise are 
questionable” for several reasons.
122
  First, they contend that the im-
provement of analytical tools means that the ability to find differenc-
es between reference and follow-on products will only increase, while, 
in most cases, the consequences of these differences remain un-
known.
123
  What is more, such differences are irrelevant if the clinical 
data shows the products to be clinically equivalent.
124
 
Second, Schellekens and Moors note that biosimilar manufac-
turers actually use state-of-the-art technology, while older technolo-
gies often constrain brand manufacturers because of the costs and 
regulatory hurdles involved in updating their practices.
125
  Thus, they 
maintain that “it seems much more logical for regulators to expect 
biosimilars to be producted by the best technology on offer rather 
than to mandate that they are made of comparable quality to the 
brands.”
126
 
Third, according to Schellekens and Moors, comparative phar-
macokinetic trials are of limited usefulness for many reasons.  For ex-
ample, “the acceptance range for pharmacokinetics parameters be-
 
 118 EMA, Questions and Answers on Recommendation for Refusal of Marketing Application 
for Alpheon, at 1, EMEA Doc. No. 190896/2006 (June 28, 2006), available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_
-_Initial_authorisation/human/000585/WC500017451.pdf. 
 119 Id. 
 120 Id. at 2. 
 121 Schellekens & Moors, supra note 4, at 30–31. 
 122 Id. at 30. 
 123 Id. 
 124 Id. 
 125 Id. at 31. 
 126 Id.  
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tween biosimilar and reference product are difficult or impossible to 
predefine and justify,” and the relationships between such parame-
ters and actual clinical effects are unclear.
127
 
Thus, Schellekens and Moors advocate the end of the regulatory 
requirement for a comparability exercise for biosimilars.
128
  They ac-
knowledge that comparisons between reference and follow-on biolog-
ics are useful during the development of biosimilars to set specifica-
tions for production and purification, to validate production 
methods and analytical tools, for marketing purposes, and perhaps to 
claim extrapolation of an indication.
129
  Nonetheless, they believe that 
discontinuation of the comparability exercise will hasten the creation 
of biosimilars that are more complex.
130
  At present, however, the 
comparability exercise remains firmly entrenched as a regulatory re-
quirement for approval of follow-on biologics. 
B. The Difficulty of Assessing Interchangeability of the Reference and 
Biosimilar Products 
Once a biosimilar product has been adjudged comparable to the 
reference product, it can also be evaluated for interchangeability.  
According to the BPCIA, a biological product is acknowledged to be 
interchangeable with a reference product if it is biosimilar to the ref-
erence product and “can be expected to produce the same clinical 
result as the reference product in any given patient.”
131
  A pharmacy 
can then substitute interchangeable products in place of a branded 
product without the knowledge or approval of a physician.
132
 
The BPCIA is unique in providing a means of approving a fol-
low-on biologic either as a “stand-alone product” or as interchangea-
ble with a reference product.
133
  The EMA has taken the position, 
 
 127 Schellekens & Moors, supra note 4, at 30–31. 
 128 Id. 
 129 Id. 
 130 Id.  
 131 42 U.S.C. § 262(k)(4)(A)(ii) (Supp. IV 2010).  Furthermore, if a biological 
product “is administered more than once to an individual,” it will be deemed inter-
changeable only if “the risk in terms of safety or diminished efficacy of alternating or 
switching between use of the biological product and the reference product is not 
greater than the risk of using the reference product without such alternation or 
switch.”  § 262(k)(4)(B).     
 132 See § 262(k)(4).  The term “interchangeability” has a similar meaning in the 
EU.  See Mellstedt et al., supra note 1, at 416 (“Automatic substitution allows for the 
dispensing of generic drugs in place of prescribed innovator products by pharmacists 
without the knowledge or consent of the treating physician.”). 
 133 Cf. Ywe J. Looper, Legislative Initiatives in Europe, Canada and the United States for 
Market Authorization of Follow-on Biologics, 13 CURRENT OPINION IN DRUG DISCOVERY & 
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through its Executive Director Thomas Lonngren, that “[i]t is not 
possible [the EMA] would guarantee a biosimilar is interchangeable 
(with its originator).”
134
  Instead, substitution is a matter for regula-
tors in each individual member nation.
135
  Although Lonngren con-
cedes that the EMA’s scientists are probably best placed to decide if a 
biosimilar is similar enough to its reference product to be substituta-
ble, he notes that the authority to answer this question has tradition-
ally belonged to national health systems, and, therefore, remains out-
side the EMA’s remit.
136
  Indeed, an official EMA statement in 2007 
declared that “[s]ince biosimilar and biological reference medicines 
are similar but not identical, the decision to treat a patient with a ref-
erence or a biosimilar medicine should be taken following the opi-
nion of a qualified health-care professional.”
137
 
Experts have noted several reasons why automatic substitution is 
not appropriate for biologics, even though some U.S. states and EU 
nations do permit automatic substitution for certain traditional 
chemical pharmaceuticals.
138
  First, “biosimilars are not generic ver-
sions of innovator products, and there will be limited clinical expe-
rience with biosimilars at the time of approval,” and “[s]mall differ-
ences between biosimilars and innovator products may affect clinical 
outcomes.”
139
  Moreover, if countries permit automatic substitution, 
patients could receive multiple biopharmaceutical products over the 
course of a therapy, making it difficult to determine the cause of any 
adverse events.
140
 
Recently, both France and Spain enacted legislation banning the 
automatic substitution of biosimilars for branded products without 
 
DEV. 247, 252 (2010) (discussing the United States’ unique approach to interchan-
geability in the context of draft biosimilar legislation that was previously proposed in 
the United States). 
 134 Nick Smith, EMEA “Will Not Guarantee” That Biosimilars Are Interchangeable With 
Originator, APM HEALTH EUROPE, July 21, 2006, http://www.apmhealtheurope.com/ 
depechesPublieesDepeches.php?annee=2006&mois=7&jour=21 (citing EMA Execu-
tive Director Thomas Lonngren).   
 135 See id. 
 136 Id.   
 137 EMA, Questions and Answers on Biosimilar Medicines (Similar Biological Medicinal 
Products), at 1, EMEA Doc. No. 74562/2006 (Apr. 19, 2007), available at www.ebe-
biopharma.org/documents/biosimilars/biosimilars_q+and+a.pdf. 
 138 Mellstedt et al., supra note 1, at 416.  Indeed, mandatory substitution laws in 
many U.S. states require pharmacists, when presented with a brand-name prescrip-
tion, to substitute it with the generic version.  See John A. Vernon et al., Exploration of 
Potential Economics of Follow-on Biologics and Implications for Data Exclusivity Periods for 
Biologics, 16 B. U. J. SCI. & TECH. L. 55, 67 (2010). 
 139 Mellstedt et al., supra note 1, at 416. 
 140 Id. 
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the express consent of the prescribing physician.
141
  Research has not 
revealed any instance of an EU member state approving the automat-
ic substitution of a biologic.  Concomitantly, some U.S. commenta-
tors express doubt that the FDA will designate follow-on biologics as 
interchangeable with reference products and suggest that follow-on 
products will “[m]ost likely will be treated as therapeutic alternatives 
by health care providers, which will limit their uptake in the market 
relative to generic pharmaceuticals.”
142
  Another open question in the 
United States is whether there will be a federal determination of in-
terchangeability as opposed to a decision at the state level. 
It is interesting to note, however, that, notwithstanding the 
French legislature’s ban on any substitute for biosimilars without the 
express consent of the prescribing physician,
143
 three French medical 
societies relating to nephrology seek to foster substitutability for bio-
similiars as a means of better serving their patients.
144
  These groups 
have considered the creation of a “biosimilar repertory,” which would 
allow for a period of two to three years to study the use of biosimilars 
prescribed to treat kidney disease, and gather the appropriate phar-
macoviligance data.
145
  The repertory would ultimately permit substi-
tution by the pharmacist “on the condition that the doctor hasn’t 
specified on the prescription that the prescribed product isn’t substi-
tutable.”
146
  In praising this possibility, Elisabeth Berthet-Maillols ex-
presses skepticism that any ban on substitutability is free from influ-
ence from the concerned innovator labs, which have a strong stake in 
preventing substitution.
147
 
C. The Establishment of Immunogenicity Testing, Pharmacovigilance, 
and Risk Management Plans 
EMA guidelines require immunogenicity testing and pharmaco-
vigilance programs to monitor the efficacy and safety of biosimilar 
products post-approval.
148
  Post-approval safety testing is particularly 
 
 141  C. Fernandez et al., Biosimilars:  What Pharmacists Need to Know, 15 EUR. J. HOSP. 
PHARMACY PRAC. 41, 43 (2009); Schellekens, supra note 7, at i32.  While seven other 
E.U. member nations also ban automatic substitution, they in fact do so for all phar-
maceuticals, both chemical and biological. 
 142 Vernon et al., supra note 138, at 67. 
 143 See Schellekens, supra note 7, at i32. 
 144 See Berthet-Maillols, supra note 45, at 124. 
 145 Id. 
 146 Id. (citation omitted). 
 147 See id. 
 148 See supra notes 64–65 and accompanying text. 
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important with respect to biosimilars because there is limited clinical 
data available at the time of their approval since comprehensive clini-
cal testing is often not required.
149
  Moreover, pharmacovigilance 
programs are useful in terms of assessing product safety for specific 
patient populations, which is particularly important for the safe use 
of biosimilars in therapeutic indications for which the product may 
not have been formally evaluated, such as for an extrapolated indica-
tion.
150
 
The importance of post-marketing pharmacovigilance is hig-
hlighted by Johnson & Johnson’s Eprex, a blockbuster erythropoie-
tin-reference product, which gave rise to the potentially fatal condi-
tion of pure red cell aplasia in patients after a formulation change.
151
  
In addition, after the approval of the biosimilar-growth hormone 
Omnitrope, immunogenicity issues arose.  During development, pro-
duction of Omnitrope had been transferred from one manufacturing 
facility to another.
152
  Although qualitative testing demonstrated no 
significant differences between the end products of these facilities, 
the products exhibited different immunogenicity profiles, an occur-
rence that the manufacturer was able to rectify prior to approval.
153
 
Both the EMA in the EU and the FDA in the United States have 
established rigorous pharmacovigilance programs for the monitoring 
of adverse events relating to all medicinal products, not only biosimi-
lars.
154
  As explained by Laura Faden and Christopher-Paul Milne, 
both regions have implemented procedures for post-marketing sur-
veillance (PMS), post-approval research (PAR), and risk manage-
ment.
155
  PMS involves collecting information on outcomes from med-
ical professionals, patients, and manufacturers, either passively, such 
as through reports of adverse events, or actively, via data-mining of 
health records from third-party payers or registries.
156
  PAR encom-
passes follow-up studies or surveys aimed at determining the magni-
tude and frequency of adverse events related to a particular medicin-
al product and attempts to discern whether reported adverse health 
 
 149 See Mellstedt et al., supra note 1, at 415. 
 150 See id. at 415–16. 
 151 See Gitter, supra note 4, at 605–06. 
 152 See Mellstedt et al., supra note 1, at 414–15. 
 153 See id. 
 154 See Laura B. Faden & Christopher-Paul Milne, Pharmacovigilance Activities in the 
United States, European Union, and Japan: Harmonic Convergence of Convergent Evolution?, 
63 FOOD & DRUG L.J. 683, 683–84 (2008). 
 155 Id. at 684–85. 
 156 Id. 
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effects are actually causally related to the product under investiga-
tion.
157
  Risk management entails the use of PMS and PAR data to de-
velop means of preventing or reducing the potential risks that medi-
cinal products pose and may include planning, education, and 
communication measures.
158
 
Experts have noted two significant differences, however, be-
tween pharmacovigilance in the EU and the United States.  First, 
PMS in Europe is “more inclusive” than in the United States with re-
spect to “compiling adverse event reports and data from sources 
worldwide” and has traditionally advocated “a more compulsory ap-
proach toward assessment of data” for signs of adverse events.
159
  
Second, with respect to biosimilars in particular, the EU requires a 
risk management plan (RMP) for all biosimilars that receive approval 
through the centralized procedure
160
 as well as for all drugs with new 
active ingredients.
161
  For example, the EU RMP for all erythropoeitin 
biosimilars provides that, with respect to risks of thrombotic-vascular 
events, the Summary of Product Characteristics (SMPC), which is 
submitted with the application for marketing authorization and pro-
vides information for medical professionals as to the use of the prod-
uct,
162
 should state that the target hemoglobin not exceed 12 g/dl.
163
  
With respect to the increased incidence of pure red cell aplasia with 
off-label subcutaneous use in renal-failure patients, the EU RMP pro-
vides for the creation of an SMPC that warns of this risk and for the 
widespread distribution of an educational leaflet to health-care pro-
viders.
164
 
The United States is increasingly harmonizing its approach to 
post-market safety in accordance with the EU approach, however, in 
light of its newly adopted abbreviated-approval pathway for biosimi-
lars that tracks the EU system.  Drug sponsors, who frequently seek 
 
 157 Id. 
 158 Id.  
 159 Id. at 697. 
 160 See supra note 61 and accompanying text for a discussion of the EU’s centra-
lized regulatory process. 
 161 See Faden & Milne, supra note 154, at 697; see also EMA, Guideline on Risk Man-
agement Systems for Medicinal Products for Human Use, at 7, EMEA Doc. No. 
CHMP/96268/2005 (Nov. 14, 2005), available at http://web.invima.gov.co/portal/ 
documents/BVSalud/IVC/anexo5emeagrmsmp.pdf. 
 162 EUROPEAN COMM’N, ENTER. & INDUS. DIRECTORATE-GEN., A GUIDELINE ON 
SUMMARY OF PRODUCT CHARACTERISTICS 1 (Oct. 2005), available at 
http://ec.europa.eu/health/files/eudralex/vol-2/c/spcguidrev1-oct2005_en.pdf. 
 163 See Berthet-Maillols, supra note 45, at 120. 
 164 See id. at 120–21.  
GITTER.DOCX (DO NOT DELETE) 4/12/2011  8:37 AM 
2011] THE EUROPEAN UNION EXPERIENCE 585 
approval in both regions, favor harmonization.
165
  The U.S. Food and 
Drug Administration Amendments Act of 2007
166
 minimizes the gap 
between the EU, which requires comprehensive post-marketing safety 
data, and the United States, which traditionally has not, by granting 
the FDA the authority to require manufacturers to collect patient 
safety data in the form of a Risk Evaluation and Mitigation Strategy 
(REMS).
167
  The FDA will require a REMS, an analogue to the EU 
RMP,
168
 if the FDA determines that a risk-management approach is 
necessary in order to ascertain that the benefits of the product out-
weigh its risks.
169
  Nonetheless, in contrast to the EU, a REMS is re-
quired in the United States only if the FDA determines that it is ne-
cessary.
170
  Generally, the FDA does not require a REMS if a product’s 
labeling is adequate to establish that the benefits for that user out-
weigh its risks.
171
 
Harmonization efforts operate on an international level as well.  
The International Conference on Harmonisation of Technical Re-
quirements for Registration of Pharmaceuticals for Human Use, 
which is made up of regulatory bodies, pharmacopeias, and drug-
industry members from the United States, Europe, and Japan, has 
created a guidance document on pharmacovigilance planning for 
drugs approved in the United States, EU, and Japan.
172
 
The pharmacovigilance and risk-management processes relating 
to biosimilars loom very large because of the safety concerns that bio-
similars in developing nations raise.
173
  Berthet-Maillols notes, howev-
er, that similar issues have not arisen with biosimilars that the EMA 
 
 165 See Faden & Milne, supra note 154, at 696. 
 166 Pub. L. No. 110-185, 121 Stat. 926. 
 167 See Faden & Milne, supra note 154, at 687. 
 168 See Cheryl Key et al., The Value of Reviewing Existing EU Risk Management Plans, 
RAJ PHARMA, Feb. 2010, at 79, available at http://www.quintiles.com/ 
elements/media/inthenews/reviewing-existing-risk-management-plans.pdf. 
 169 See Faden & Milne, supra note 154, at 687. 
 170 See id. 
 171 See Key et al., supra note 168, at 79. 
 172 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS 
FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, E2E: PHARMACOVIGILANCE 
PLANNING (2002), available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_ 
Products/Guidelines/Efficacy/E2E/Concept_papers/E2E_Concept_Paper.pdf; see 
also Faden & Milne, supra note 154, at 696; Agnes Shanley, Taking the Plunge to Har-
monize Pharmaceutical Regulations, PHARMAMANUFACTURING.COM (Mar. 2010), 
http://www.pharmamanufacturing.com/articles/2010/034.html. 
 173 See Schellekens, supra note 7, at i31 (describing an immunogenic response in a 
patient using a follow-on epoetin manufactured in India). 
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has authorized, thereby demonstrating that such products are indeed 
safe when vetted via a rigorous approval process.
174
 
D. The Naming of Follow-On Biological Products 
The WHO provides guidance for naming biologic products.  
The WHO grants each pharmaceutical substance an International 
Nonproprietary Name (INN), or generic name,
175
 guided by an inter-
national expert advisory panel.
176
  According to the WHO, “INN[s] 
are selected in principle only for single, well-defined substances that 
can be unequivocally characterized by a chemical name (or formu-
la)”; they are not given to mixtures of substances or substances that 
are not well-characterized.
177
  Generic chemical drugs typically receive 
the same INN as the reference drug because “the active ingredient of 
the generic is considered to be an exact copy of the active ingredient 
of the reference drug.”
178
 
Similarly, the WHO has determined that INNs should be given 
to biosimilars based on their active ingredient, provided the assess-
ment of active ingredient is sufficiently consistent and precise.
179
  
Thus, even though biologics are not well-characterized, the WHO 
notes that INNs have “been assigned to biological medicines since the 
early days of the programme, including biotechnology derived prod-
ucts such as monoclonal antibodies and a range of recombinant DNA 
derived proteins.”
180
  For example, the brand name forms of human 
growth hormone, Genotrope and Humatrope, share the same INN: 
somatropin.
181
  In addition, the biosimilars that used these branded 
forms as their reference molecules, Omnitrope and Valtropin, also 
share that same INN.
182
 
INNs are intended for use in pharmacopoeias, labeling, product 
information, advertising and other promotional material, drug regu-
 
 174 See Berthet-Maillols, supra note 45, at 119. 
 175 Medicines: International Nonproprietary Names, WORLD HEALTH ORG., 
http://www.who.int/medicines/services/inn/en (last visited Mar. 2, 2011). 
 176 Mellstedt et al., supra note 1, at 416. 
 177 Guidance on INN, WORLD HEALTH ORG., http://www.who.int/medicines/ 
services/inn/innguidance/en/index.html (last visited Mar. 2, 2011). 
 178 CHU & PUGATCH, supra note 15, at 12 n.29. 
 179 WORLD HEALTH ORG., INFORMAL CONSULTATION ON INTERNATIONAL 
NONPROPRIETARY NAMES (INN) POLICY FOR BIOSIMILAR PRODUCTS 4–6 (2006), available 
at http://www.who.int/medicines/services/inn/BiosimilarsINN_Report.pdf. 
 180 Id. at 5. 
 181 See Liang, supra note 17, at 424. 
 182 See id.  Although biosimilars share the same INN as the reference product, they 
are required to have a separate trade name.  See CHU & PUGATCH, supra note 15, at 21. 
GITTER.DOCX (DO NOT DELETE) 4/12/2011  8:37 AM 
2011] THE EUROPEAN UNION EXPERIENCE 587 
lation and scientific literature, and as a basis for generic product 
names.  Jurisdictions such as the EU, Japan, and the United States 
have agreed to harmonize, in large measure, their naming of bio-
pharmaceuticals through the adoption of INNs.
183
  Once it assigns an 
INN, the WHO formally places it in the public domain, which rend-
ers that INN truly nonproprietary and means that the INN can be 
used without any restriction whatsoever to identify pharmaceutical 
substances.
184
 
There is debate with respect to the attribution of INNs to biolog-
ical products among WHO officials, as well as among manufacturers 
of reference and follow-on products, professional medical societies, 
and academics.
185
  In a 2006 consultation paper summarizing a meet-
ing between WHO officials and representatives of various national 
regulatory agencies, the WHO asserted that “the concept of a biosimi-
lar product is regulatory in nature, whereas assignment of an INN is a 
nomenclature process based on scientific characterization of an ac-
tive pharmaceutical substance.”
186
  The WHO noted that there was 
“complete agreement amongst the national regulatory authorities 
present,” including from the EU EMA and the U.S. FDA, that “[t]he 
assignment of INNs should be independent of the regulatory process 
or of considerations of prescribing interchangeability or the use of 
INNs in pharmacovigilance.”
187
  Therefore, “it was recommended that 
no distinctive designation to indicate the regulatory term biosimilar 
be built into the INN for these products.  Instead, it was proposed 
that INN policy for naming biosimilars be the same as that for stand 
alone biologicals.”
188
  One caveat to this recommendation, however, is 
that differences in glycosolation
189
 have been handled by giving an 
INN name that adds a Greek letter spelled out as a second word (for 
example, epoetin alpha, epoetin beta).
190
 
Various scholars have suggested, however, that the pharmacovi-
gilance process would benefit from the assignment of unique INNs to 
biopharmaceuticals because it would facilitate accurate prescribing 
and dispensing and properly link any adverse event to the specific 
 
 183 WORLD HEALTH ORG., supra note 179, at 5. 
 184 Id. 
 185 See Berthet-Maillols, supra note 45, at 121–22 (describing the debate among 
many stakeholders concerned about the INN process). 
 186 WORLD HEALTH ORG., supra note 179, at 7. 
 187 Id. at 10. 
 188 Id. 
 189 See supra note 73 and accompanying text. 
 190 WORLD HEALTH ORG., supra note 179, at 5–6. 
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product.  For example, three prominent European oncologists sug-
gest that the WHO ought to “assign unique INNs to biopharmaceuti-
cals.”
191
  Likewise, Schellekens contends that “[u]nique naming for all 
biopharmaceuticals would likely help to differentiate these products, 
which would facilitate accurate prescribing, dispensing and pharma-
covigilance.”
192
 
Other experts disagree with the notion of unique naming for bi-
opharmaceuticals, so as to differentiate each biosimilar product from 
its reference product and from other follow-on protein products.  Ac-
cording to Berthet-Maillols, once the comparability exercise has been 
performed and a marketing authorization has been granted, “it 
would be scientifically inconsistent to ask a company to apply for a 
different INN for a biosimilar product.”
193
  By that logic, the reference 
product would itself require a new INN each time it was not found to 
be identical to its earlier formulation.
194
 
Berthet-Maillols also notes that the EMA regulations already re-
quire that biosimilars be prescribed by their approved names, mean-
ing either their trade name or a scientific denomination accompa-
nied by a trademark, or by the holder of the marketing 
authorization.
195
  Furthermore, side effects must be reported by iden-
tifying the name of the medicinal product and the batch number, not 
simply an INN.  She cites one study, performed before batch num-
bers were required to accompany reports of side effects, showing that 
of 8970 reports concerning the biologic drug erythropoietin, doctors 
had included the full product name, rather than merely the INN, ni-
nety-nine percent of the time.
196
  Thus, Berthet-Maillols concludes 
that “[d]octors seem to have integrated on their own the necessity, 
regarding the traceability of biotechnology medicines” by mentioning 
the full product name and not only the INN;
197
 therefore, “the attri-
bution of an INN different from that of the [reference product] for 
each of its biosimilars does not seem to be necessary in the name of 
ensuring the pharmacovigilance of biotechnology products.”
198
 
Experts also argue that, in addition to unique naming, more 
comprehensive labeling of biosimilars would assist physicians and 
 
 191 Mellstedt et al., supra note 1, at 416.   
 192 Schellekens, supra note 7, at i34. 
 193 Berthet-Maillols, supra note 45, at 122 (citations omitted). 
 194 Id. 
 195 Id. 
 196 Id. 
 197 Id. 
 198 Id. 
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pharmacists in decision-making.  According to Mellstedt et al., 
“[b]ecause biosimilars are not equivalent to reference products and 
because unique efficacy and safety data will be available, labeling 
should include these data . . . [and] those indications that are based 
upon extrapolation of data.”
199
  Schellekens agrees that “[t]he labels 
of the approved biosimilars are nearly identical or are very similar to 
those of the reference product.  A more transparent label that in-
cluded relevant clinical data for the biosimilar, such as the data in-
cluded in EPAR [European Public Assessment Reports], would help 
clinicians make informed treatment decisions.”
200
 
E. Extrapolation of Indications 
Extrapolation of indications is another issue facing the FDA as it 
develops an abbreviated approval pathway for biosimilars.  An 
“[e]xtrapolation involves the approval of a drug for indications for 
which it has not been evaluated in clinical trials.”
201
  The EMA gener-
ally supports data extrapolation for biosimilars that make the requi-
site scientific showing on the theory that if the biosimilar shows ade-
quate comparability to the reference product for one indication, it 
may be reasonable to extend the biosimilar’s approval to other indi-
cations of the innovator product.
202
 
The EU’s current guidance with respect to biosimilars provides 
that if a reference product “has more than one indication, the effica-
cy and safety of the medicinal product claimed to be similar has to be 
justified or, if necessary, demonstrated separately for each of the 
claimed indications.”
203
  But “[i]n certain cases it may be possible to 
extrapolate therapeutic similarity shown in one indication to other 
indications of the reference medicinal product.”
204
  A sufficient show-
ing will depend, inter alia, on clinical experience, available literature 
and data, and whether the same mechanisms of action or the same 
receptor(s) are involved in all indications.
205
  If the mechanism of ac-
tion differs between indications, the biosimilar manufacturer may be 
 
 199 Mellstedt et al., supra note 1, at 416. 
 200 Schellekens, supra note 7, at i34.  EPARs are assessment reports for the evalua-
tion of marketing authorization applications made public by the EMA on its website.  
Key et al., supra note 168, at 80.  
 201 Mellstedt et al., supra note 1, at 417.  
 202 Id. 
 203 EMA, EMEA/CHMP/BWP/42832/2005, supra note 64, at 3. 
 204 Id. 
 205 See id. 
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required to provide additional clinical data.
206
  One example of 
extrapolation involves the biosimilar human growth hormone Omni-
trope and its reference product Genotropin.
207
  Although efficacy and 
safety studies between the two products were conducted only in 
children with growth disorders, the product labeling for Omnitrope 
is “virtually identical to that of the reference product, including the 
indication for use in adults.”
208
 
As Mellstedt notes, although extrapolation is appropriate for 
well-characterized proteins such as human growth hormones, it may 
not apply in cases involving more complex biopharmaceutical prod-
ucts or high-risk populations.
209
  This issue will be especially important 
for the development of monoclonal antibodies, which are very com-
plex biopharmaceuticals that constitute the fastest-growing sector of 
the biopharmaceutical industry and for which many initial patents 
will expire in 2014.
210
 
F. The Possibility of Extensions to the Term of Data Exclusivity 
As noted previously, the EU affords ten years of data exclusivity 
to biologics that have received a marketing authorization.
211
  In addi-
tion, an innovator may obtain an additional year of data exclusivity if 
it obtains authorization for new therapeutic indication(s) which 
bring(s) significant clinical benefits in comparison with existing ther-
apies.
212
  The EU considers the initial marketing authorization in Eu-
rope to be a “global marketing authorization, which covers all varia-
tions in drug strength, formulation, route of administration, or 
change in manufacturing procedure that are subsequently authorized 
to the original licensor.”
213
  Thus, “all of these variations are consi-
dered to have a single period of data exclusivity that is timed from the 
initial market authorization.”
214
 
 
 206 See Mellstedt et al., supra note 1, at 417. 
 207 See id. 
 208 Id. 
 209 Id. 
 210 See Ciftci, supra note 65. 
 211 See supra note 45 and accompanying text. 
 212 See supra note 46 and accompanying text. 
 213 Looper, supra note 133, at 253. 
 214 Id. (citing Directive 2004/27/EC, of the European Parliament and of the 
Council of 31 March 2004 Amending Directive 2001/83/EC on the Community 
Code Relation to Medicinal Products for Human Use—Amendment to Article, 2004 
O.J. (L136) 34, 34–57.). 
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Like the EU regulatory scheme, the BPCIA does not provide for 
renewal of data exclusivity in favor of a sponsor of a reference prod-
uct in case of changes in drug strength, formulation, or route of ad-
ministration.
215
  Despite this similarity, the BPCIA also differs from EU 
law in a few significant ways.  First, the BPCIA does not provide for 
renewal of data exclusivity for an innovator firm in case of changes in 
indication.
216
  Second, the BPCIA will consider the renewal of data 
exclusivity in the case of a structural modification to a reference 
product that results in a change in safety, purity, or potency com-
pared to the original product.
217
 
Looper notes that “[t]he eligibility of a second-generation bio-
logical product with structural modifications (e.g., PEGylation or gly-
cosylation) and concomitant improvements in efficacy, safety or re-
lease profiles for consideration as a distinct biological product for the 
purposes of data protection in Europe . . . has not been estab-
lished.”
218
  Because second-generation biological products that have 
obtained market authorization as follow-on biologics cannot be used 
as reference products by manufacturers of future follow-on biolog-
ics,
219
 there is limited social value in permitting makers of follow-on 
biologics to obtain data exclusivity. 
This may change, however.  As Falk Ehmann of the EMA notes, 
the EMA must consider whether the regulatory pathway for biosimi-
lars may be a two-way street, that is, whether such that a reference 
product would ultimately be able to refer to characteristics of its 
counterpart biosimilar, such as the biosimilar’s dosing, route of ad-
ministration, and indication.
220
  Such an approach would undoubted-
ly expedite the drug development and approval process, redounding 
to the benefit of consumers. 
 
 215 42 U.S.C. § 262(k)(7)(C) (Supp. IV 2010). 
 216 Looper, supra note 133, at 253. 
 217 § 262(k)(7)(C). 
 218 Looper, supra note 133, at 253. 
 219 Id. at 248 (stating that EU law requires a reference product “to have received 
market authorization through the standard drug licensure process”).  In the United 
States as well, a reference product must have been approved in the United States.  See 
§ 262(i)(3). 
 220 FALK EHMANN, BIOSIMILARS IN THE EUROPEAN UNION—EXPERIENCE GAINED AND 
PERSPECTIVES 32 (2008), available at http://www.biosimilarstoday.com/ 
2008/Ehmann.pdf. 
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V. CONCLUSION 
With the enactment of the Biologics Price Competition and In-
novation Act of 2009, the U.S. FDA will issue guidance for manufac-
turers of follow-on biologics.  Foremost among the issues faced by the 
FDA are the assessment of comparability of the reference and follow-
on biologic products; the interchangeability of the follow-on and ref-
erence products; the appropriate levels of immunogenicity testing, 
pharmacovigilance and risk assessment for biosimilars; the naming of 
follow-on biologics; the approval of a biosimilar drug for indications 
for which it has not been evaluated in clinical trials, based on extra-
polation of data from the reference product; and potential exten-
sions to the term of data exclusivity for biosimilars.  These issues have 
been, or presently are, under discussion in the EU. 
While the United States will certainly look to the EU in develop-
ing its abbreviated pathway, with the passage of time, the EU will be 
influenced by developments in the United States, thereby fostering 
harmonization between the jurisdictions.  For example, the BPCIA 
allows for the possibility of the renewal of data exclusivity in the case 
of a structural modification to a reference product that results in a 
change in safety, purity, or potency compared to the original prod-
uct.  This possibility creates an incentive to develop second-
generation follow-on protein products.  If, along with this provision, 
legislation were enacted that would permit a reference product to re-
ly on data produced by the manufacturer of the follow-on product, 
this reliance would create a feedback loop that would dramatically 
expedite biosimilar drug development and the approval process.  In 
this way, the BPCIA could truly revitalize the biosimilar industry, 
which would contribute immeasurably to public health. 
 
